NIDAN LABS AND HEALTH LTD vs TORRENT PHARMACEUTICALS L
A side-by-side comparison of NIDAN LABS AND HEALTH LTD (NIDAN) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, TORRENT PHARMACEUTICALS L leads NIDAN vs TORNTPHARM on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability22
- Growth02
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
TORNTPHARM takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Stock is trading at 0.27 times its book value", "Company's working capital requirements have reduced from 87.8 days to 33.6 days"]
- − ["Though the company is reporting repeated profits, it is not paying out dividend", "The company has delivered a poor sales growth of 4.62% over past five years.", "Company has a low return on equity of 1.81% over last 3 years.", "Promoter holding has decreased over last 3 years: -14.2%"]
- + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
- − ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

